Cargando…

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study

INTRODUCTION: Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546486/
https://www.ncbi.nlm.nih.gov/pubmed/33035259
http://dx.doi.org/10.1371/journal.pone.0240489
_version_ 1783592238684569600
author Evans, Alison
Davies, Miranda
Osborne, Vicki
Roy, Debabrata
Shakir, Saad
author_facet Evans, Alison
Davies, Miranda
Osborne, Vicki
Roy, Debabrata
Shakir, Saad
author_sort Evans, Alison
collection PubMed
description INTRODUCTION: Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated to collect further information on the safety and utilisation of rivaroxaban in a broader range of patient groups in routine clinical practice. METHODS AND RESULTS: The ROSE study was conducted in hospitals in England and Wales. Consenting adults with non-valvular atrial fibrillation newly started on rivaroxaban were eligible and followed up for 12 weeks. Data was derived through secondary use of medical records. The primary outcome was major bleeding within gastrointestinal, urogenital and intracranial sites. A total of 4846 patients were enrolled in the study September 2013 to January 2016, 965 of which were treated with rivaroxaban for non-valvular atrial fibrillation. The median age in the rivaroxaban non-valvular atrial fibrillation cohort was 76 years, 53.6% were male. The median HAS-BLED score was 2 and the median CHA(2)DS(2)-VASc score was 4. The risk of major bleeding within each of the primary sites of gastrointestinal, urogenital and intracranial during the 12 week observation period was low (0.2%; n = 2). The risk of major bleeding in all sites was 1.0% (n = 10) at a rate of 5.5 events per 100 patient years. CONCLUSION: In terms of the primary outcome risk of major bleeding within gastrointestinal, urogenital and intracranial sites during the 12 week observation period, the risk estimates in the non-valvular atrial fibrillation rivaroxaban user population were low (<1%), and consistent with risk estimated from clinical trial data and in routine clinical practice.
format Online
Article
Text
id pubmed-7546486
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75464862020-10-19 Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study Evans, Alison Davies, Miranda Osborne, Vicki Roy, Debabrata Shakir, Saad PLoS One Research Article INTRODUCTION: Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated to collect further information on the safety and utilisation of rivaroxaban in a broader range of patient groups in routine clinical practice. METHODS AND RESULTS: The ROSE study was conducted in hospitals in England and Wales. Consenting adults with non-valvular atrial fibrillation newly started on rivaroxaban were eligible and followed up for 12 weeks. Data was derived through secondary use of medical records. The primary outcome was major bleeding within gastrointestinal, urogenital and intracranial sites. A total of 4846 patients were enrolled in the study September 2013 to January 2016, 965 of which were treated with rivaroxaban for non-valvular atrial fibrillation. The median age in the rivaroxaban non-valvular atrial fibrillation cohort was 76 years, 53.6% were male. The median HAS-BLED score was 2 and the median CHA(2)DS(2)-VASc score was 4. The risk of major bleeding within each of the primary sites of gastrointestinal, urogenital and intracranial during the 12 week observation period was low (0.2%; n = 2). The risk of major bleeding in all sites was 1.0% (n = 10) at a rate of 5.5 events per 100 patient years. CONCLUSION: In terms of the primary outcome risk of major bleeding within gastrointestinal, urogenital and intracranial sites during the 12 week observation period, the risk estimates in the non-valvular atrial fibrillation rivaroxaban user population were low (<1%), and consistent with risk estimated from clinical trial data and in routine clinical practice. Public Library of Science 2020-10-09 /pmc/articles/PMC7546486/ /pubmed/33035259 http://dx.doi.org/10.1371/journal.pone.0240489 Text en © 2020 Evans et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Evans, Alison
Davies, Miranda
Osborne, Vicki
Roy, Debabrata
Shakir, Saad
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title_full Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title_fullStr Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title_full_unstemmed Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title_short Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
title_sort incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: results from the rivaroxaban observational safety evaluation (rose) study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546486/
https://www.ncbi.nlm.nih.gov/pubmed/33035259
http://dx.doi.org/10.1371/journal.pone.0240489
work_keys_str_mv AT evansalison incidenceofmajorandclinicallyrelevantnonmajorbleedinginpatientsprescribedrivaroxabanforstrokepreventioninnonvalvularatrialfibrillationinsecondarycareresultsfromtherivaroxabanobservationalsafetyevaluationrosestudy
AT daviesmiranda incidenceofmajorandclinicallyrelevantnonmajorbleedinginpatientsprescribedrivaroxabanforstrokepreventioninnonvalvularatrialfibrillationinsecondarycareresultsfromtherivaroxabanobservationalsafetyevaluationrosestudy
AT osbornevicki incidenceofmajorandclinicallyrelevantnonmajorbleedinginpatientsprescribedrivaroxabanforstrokepreventioninnonvalvularatrialfibrillationinsecondarycareresultsfromtherivaroxabanobservationalsafetyevaluationrosestudy
AT roydebabrata incidenceofmajorandclinicallyrelevantnonmajorbleedinginpatientsprescribedrivaroxabanforstrokepreventioninnonvalvularatrialfibrillationinsecondarycareresultsfromtherivaroxabanobservationalsafetyevaluationrosestudy
AT shakirsaad incidenceofmajorandclinicallyrelevantnonmajorbleedinginpatientsprescribedrivaroxabanforstrokepreventioninnonvalvularatrialfibrillationinsecondarycareresultsfromtherivaroxabanobservationalsafetyevaluationrosestudy